The Lynx Group

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Conference Correspondent — June 1, 2020
Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.
Read Article

Conference Correspondent — June 1, 2020
The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented.
Read Article

Conference Correspondent — June 1, 2020
The characteristics of long-term responders to PD-1 blockade are presented.
Read Article

Conference Correspondent — June 1, 2020
For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit.
Read Article

Conference Correspondent — June 1, 2020
Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy.
Read Article

Conference Correspondent — May 31, 2020
Approximately 30% of patients with non–small-cell lung cancer present with early-stage (I-IIIA) disease and undergo surgery. Researchers assessed the use of adjuvant osimertinib in this population.
Read Article

Conference Correspondent — May 31, 2020
Despite the approval of immune checkpoint inhibitors for patients with lung cancers, their role in rare pulmonary tumors, such as large-cell neuroendocrine carcinoma of the lung, has remained unclear.
Read Article

Conference Correspondent — May 31, 2020
Patients with platinum-pretreated small-cell lung cancer may benefit from combination use of cediranib, an oral VEGF inhibitor, and olaparib, a PARP inhibitor.
Read Article

Conference Correspondent — May 31, 2020
Developing novel targeted therapies for patients with cancer who have rare mutations, such as PI3K/AKT/mTOR pathway alterations, is particularly challenging for researchers.
Read Article

Conference Correspondent — May 31, 2020
Combining nivolumab plus ipilimumab with 2 cycles of chemotherapy may be effective in patients undergoing first-line treatment for metastatic non–small-cell lung cancer.
Read Article

Page 1 of 37

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: